AUB ScholarWorks

Haloperidol vs. ondansetron for the prevention of postoperative nausea and vomiting following gynaecological surgery

Show simple item record

dc.contributor.author Aouad M.T.
dc.contributor.author Siddik-Sayyid S.M.
dc.contributor.author Taha S.K.
dc.contributor.author Azar M.S.
dc.contributor.author Nasr V.G.
dc.contributor.author Hakki M.A.
dc.contributor.author Zoorob D.G.
dc.contributor.author Baraka A.S.
dc.contributor.editor
dc.date Feb-2007
dc.date.accessioned 2017-10-05T15:29:23Z
dc.date.available 2017-10-05T15:29:23Z
dc.date.issued 2007
dc.identifier 10.1017/S0265021506001323
dc.identifier.isbn
dc.identifier.issn 02650215
dc.identifier.uri http://hdl.handle.net/10938/15235
dc.description.abstract Background and objective: Ondansetron is widely used for the prophylaxis of postoperative nausea and vomiting, while haloperidol is an antiemetic that lacks recent data on efficacy and adverse effects. Methods: In this prospective, randomized, double-blinded study involving 93 females undergoing gynaecological procedures under general anaesthesia, we compared the efficacy and adverse effects of prophylactic haloperidol 1 mg intravenous and ondansetron 4 mg intravenous vs. placebo. Results: During the overall observation period (0-24 h), in the haloperidol, ondansetron and placebo groups respectively, the incidence of nausea and-or vomiting was 40.7percent (11-27), 48.2percent (13-27) and 55.5percent (15-27), and the need of rescue antiemetics was 22.2percent (6-27), 44.4percent (12-27) and 40.7percent (11-27), with P values 0.05 among the three groups. During the early observation period (0-2 h), in the haloperidol, ondansetron and placebo groups respectively, the incidence of nausea and-or vomiting was 13.7percent (4-29), 26.6percent (8-30) and 43percent (13-30), and the need for rescue antiemetics was 6.8percent (2-29), 26.6percent (8-30) and 36.6percent (11-30). Between haloperidol and placebo groups, the P value was 0.04 for nausea and-or vomiting, and was 0.01 for rescue antiemetics, in addition to lower nausea scores (P = 0.03). During the late observation period (2-24 h), no significant difference was shown among the three groups. Conclusion: The prophylactic administration of 1 mg intravenous haloperidol or 4 mg ondansetron, in female patients undergoing gynaecological surgery, did not improve the overall incidence of nausea and-or vomiting vs. placebo. However, haloperidol 1 mg proved to be an effective antiemetic in the early observation period without significant adverse effects. © 2006 Copyright European Society of Anaesthesiology.
dc.format.extent
dc.format.extent Pages: (171-178)
dc.language English
dc.publisher PHILADELPHIA
dc.relation.ispartof Publication Name: European Journal of Anaesthesiology; Publication Year: 2007; Volume: 24; no. 2; Pages: (171-178);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Haloperidol vs. ondansetron for the prevention of postoperative nausea and vomiting following gynaecological surgery
dc.type Article
dc.contributor.affiliation Aouad, M.T., American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon, Department of Anesthesiology, American University of Beirut Medical Center, P.O. Box 11 0236, Beirut, Lebanon
dc.contributor.affiliation Siddik-Sayyid, S.M., American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon
dc.contributor.affiliation Taha, S.K., American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon
dc.contributor.affiliation Azar, M.S., American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon
dc.contributor.affiliation Nasr, V.G., American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon
dc.contributor.affiliation Hakki, M.A., American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon
dc.contributor.affiliation Zoorob, D.G., American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon
dc.contributor.affiliation Baraka, A.S., American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon
dc.contributor.authorAddress Aouad, M.T.; Department of Anesthesiology, American University of Beirut Medical Center, P.O. Box 11 0236, Beirut, Lebanon; email: mm01@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Anesthesiology;
dc.contributor.authorDepartment Anesthesiology
dc.contributor.authorDivision
dc.contributor.authorEmail mm01@aub.edu.lb
dc.contributor.faculty Faculty of Medicine
dc.contributor.authorInitials Aouad, MT
dc.contributor.authorInitials Siddik-Sayyid, SM
dc.contributor.authorInitials Taha, SK
dc.contributor.authorInitials Azar, MS
dc.contributor.authorInitials Nasr, VG
dc.contributor.authorInitials Hakki, MA
dc.contributor.authorInitials Zoorob, DG
dc.contributor.authorInitials Baraka, AS
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Aouad, MT (reprint author), Amer Univ Beirut, Dept Anesthesiol, Med Ctr, POB 11, Beirut 0236, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097-00000542-199909000-00022; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056-NEJMoa032196; Arcioni R, 2002, ANESTH ANALG, V94, P1553, DOI 10.1097-00000539-200206000-00033; BARON MD, 1975, ANESTHESIOLOGY, V42, P508; Buttner M, 2004, ANESTHESIOLOGY, V101, P1454; Charbit B, 2005, ANESTHESIOLOGY, V102, P1094, DOI 10.1097-00000542-200506000-00006; Critchley P, 2001, J PAIN SYMPTOM MANAG, V22, P631, DOI 10.1016-S0885-3924(01)00323-2; Diemunsch P, 2000, DRUGS, V60, P533, DOI 10.2165-00003495-200060030-00002; Diemunsch P, 1999, BRIT J ANAESTH, V82, P274; DYRBERG V, 1962, ACTA ANAESTH SCAND, V6, P37, DOI 10.1111-j.1399-6576.1962.tb00102.x; Eberhart LHJ, 2002, ANAESTHESIA, V57, P1022, DOI 10.1046-j.1365-2044.2002.02822.x; Fortney JT, 1998, ANESTH ANALG, V86, P731, DOI 10.1097-00000539-199804000-00011; Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213-01.ANE.0000068580.00245.95; Graczyk SG, 1997, ANESTH ANALG, V84, P325, DOI 10.1097-00000539-199702000-00015; Habib AS, 2005, J CLIN ANESTH, V17, P62, DOI 10.1016-j.jclinane.2004.04.004; Habib AS, 2003, ANESTH ANALG, V96, P1377; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001-jama.249.13.1743; Lawrence KR, 1997, PHARMACOTHERAPY, V17, P531; Melzack R, 1989, J Pain Symptom Manage, V4, P157, DOI 10.1016-0885-3924(89)90010-9; Parlow JL, 2004, ANESTH ANALG, V98, P1072, DOI 10.1213-01.ANE.0000105880.59649.5C; Perrault LP, 2000, CAN J ANAESTH, V47, P251; Scuderi PE, 2005, ANESTHESIOLOGY, V102, P1081, DOI 10.1097-00000542-200506000-00003; Sharma ND, 1998, AM J CARDIOL, V81, P238, DOI 10.1016-S0002-9149(97)00888-6; STATILE L, 1988, GEN PHARMACOL, V19, P451, DOI 10.1016-0306-3623(88)90046-8; Sun R, 1997, ANESTH ANALG, V84, P331, DOI 10.1097-00000539-199702000-00016; TAHA S, 2005, CAN J ANAESTH, V52, P349; TORNETTA FJ, 1972, ANESTH ANAL CURR RES, V51, P964; Tramer MR, 1997, ANESTHESIOLOGY, V87, P1277, DOI 10.1097-00000542-199712000-00004; White PF, 2005, ANESTHESIOLOGY, V102, P1101, DOI 10.1097-00000542-200506000-00007; White PF, 2002, ANESTH ANALG, V95, P789, DOI 10.1213-01.ANE.0000029880.86965.E1
dc.description.citedCount 21
dc.description.citedTotWOSCount 16
dc.description.citedWOSCount 15
dc.format.extentCount 8
dc.identifier.articleNo
dc.identifier.coden EJANE
dc.identifier.pubmedID 16938159
dc.identifier.scopusID 33846062061
dc.identifier.url
dc.publisher.address 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Eur. J. Anaesth.
dc.relation.ispartOfIssue 2
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle European Journal of Anaesthesiology
dc.relation.ispartofPubTitleAbbr Eur. J. Anaesthesiol.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 24
dc.source.ID WOS:000244155400011
dc.type.publication Journal
dc.subject.otherAuthKeyword Anaesthesia general, side-effects
dc.subject.otherAuthKeyword Antiemetics, surgery gynaecological
dc.subject.otherAuthKeyword Postoperative nausea and vomiting
dc.subject.otherChemCAS cisatracurium, 96946-41-7, 96946-42-8
dc.subject.otherChemCAS droperidol, 548-73-2
dc.subject.otherChemCAS fentanyl, 437-38-7
dc.subject.otherChemCAS glycopyrronium bromide, 596-51-0
dc.subject.otherChemCAS haloperidol, 52-86-8
dc.subject.otherChemCAS isoflurane, 26675-46-7
dc.subject.otherChemCAS lidocaine, 137-58-6, 24847-67-4, 56934-02-2, 73-78-9
dc.subject.otherChemCAS neostigmine, 114-80-7, 588-17-0, 59-99-4, 8048-84-8
dc.subject.otherChemCAS nitrous oxide, 10024-97-2
dc.subject.otherChemCAS ondansetron, 103639-04-9, 116002-70-1, 99614-01-4
dc.subject.otherChemCAS paracetamol, 103-90-2
dc.subject.otherChemCAS promethazine, 58-33-3, 60-87-7
dc.subject.otherChemCAS propofol, 2078-54-8
dc.subject.otherChemCAS Antiemetics
dc.subject.otherChemCAS Haloperidol, 52-86-8
dc.subject.otherChemCAS Ondansetron, 99614-02-5
dc.subject.otherIndex anesthetic agent
dc.subject.otherIndex antiemetic agent
dc.subject.otherIndex cisatracurium
dc.subject.otherIndex droperidol
dc.subject.otherIndex fentanyl
dc.subject.otherIndex glycopyrronium bromide
dc.subject.otherIndex haloperidol
dc.subject.otherIndex isoflurane
dc.subject.otherIndex lidocaine
dc.subject.otherIndex neostigmine
dc.subject.otherIndex neuromuscular blocking agent
dc.subject.otherIndex nitrous oxide
dc.subject.otherIndex ondansetron
dc.subject.otherIndex paracetamol
dc.subject.otherIndex placebo
dc.subject.otherIndex promethazine
dc.subject.otherIndex propofol
dc.subject.otherIndex adult
dc.subject.otherIndex anesthesia induction
dc.subject.otherIndex article
dc.subject.otherIndex clinical trial
dc.subject.otherIndex controlled clinical trial
dc.subject.otherIndex controlled study
dc.subject.otherIndex double blind procedure
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug induced headache
dc.subject.otherIndex drug safety
dc.subject.otherIndex female
dc.subject.otherIndex general anesthesia
dc.subject.otherIndex gynecologic surgery
dc.subject.otherIndex human
dc.subject.otherIndex major clinical study
dc.subject.otherIndex postoperative nausea and vomiting
dc.subject.otherIndex randomized controlled trial
dc.subject.otherIndex scoring system
dc.subject.otherIndex statistical significance
dc.subject.otherIndex treatment outcome
dc.subject.otherIndex unspecified side effect
dc.subject.otherIndex Adult
dc.subject.otherIndex Analysis of Variance
dc.subject.otherIndex Anesthesia, General
dc.subject.otherIndex Antiemetics
dc.subject.otherIndex Double-Blind Method
dc.subject.otherIndex Female
dc.subject.otherIndex Gynecologic Surgical Procedures
dc.subject.otherIndex Haloperidol
dc.subject.otherIndex Humans
dc.subject.otherIndex Injections, Intravenous
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Ondansetron
dc.subject.otherIndex Postoperative Nausea and Vomiting
dc.subject.otherIndex Prospective Studies
dc.subject.otherIndex Risk Factors
dc.subject.otherIndex Time Factors
dc.subject.otherIndex Treatment Outcome
dc.subject.otherKeywordPlus INTRAVENOUS-HALOPERIDOL
dc.subject.otherKeywordPlus PATIENT SATISFACTION
dc.subject.otherKeywordPlus ANTIEMETIC ACTIVITY
dc.subject.otherKeywordPlus DOSE HALOPERIDOL
dc.subject.otherKeywordPlus CRITICALLY-ILL
dc.subject.otherKeywordPlus DROPERIDOL
dc.subject.otherKeywordPlus PROPHYLAXIS
dc.subject.otherKeywordPlus EFFICACY
dc.subject.otherKeywordPlus INTERVAL
dc.subject.otherKeywordPlus MORPHINE
dc.subject.otherWOS Anesthesiology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account